DNA-mapping technology shows promise in fight against cancer, plus more top stories in hematology/oncology
Click Here to Manage Email Alerts
Healio spoke with a member of a research team who developed a novel DNA-mapping tool that can identify gene alterations linked to cancer. This was one of the top stories in hematology/oncology last week.
Another top story was about a randomized phase 3 trial that showed luspatercept reduced the severity of anemia vs. placebo among certain patients with lower-risk myelodysplastic syndrome.
Read all last week’s top stories in hematology/oncology below.
DNA-mapping tool shows potential for identifying cancer progression
Researchers at Roswell Park Comprehensive Cancer Center and University of Buffalo have developed a novel tool to analyze a DNA-mapping technology that identifies gene alterations responsible for cancer development and progression. Read more.
Luspatercept reduces transfusion burden for certain patients with lower-risk myelodysplastic syndrome
Luspatercept reduced the severity of anemia compared with placebo among certain patients with lower-risk myelodysplastic syndrome, according to results of a randomized phase 3 trial published in The New England Journal of Medicine. Read more.
Researcher advocates ‘straight-talk’ approach for patients with advanced cancer
Shielding a patient from the facts of an advanced-cancer diagnosis could compromise the patient’s ability to make informed treatment choices, according to an article published in Journal of General Internal Medicine. Read more.
Fred Hutchinson Cancer Research Center names new president, director
Fred Hutchinson Cancer Research Center has named Thomas J. Lynch Jr., MD, as its president and director. Lynch — recognized for his expertise in solid tumor research, immuno-oncology and precision medicine — will begin his new role on Feb. 1. Read more.
Cancer mortality rate drops 29% between 1991 and 2017
The rate of cancer mortality dropped by 29% between 1991 and 2017 in the United States, with a 2.2% drop between 2016 and 2017, according to data from Cancer Statistics 2020, American Cancer Society’s annual report on cancer rates and trends. Read more.